NUS Medicine team aims to start clinical trial of targeted therapy for deadly brain cancer in 2025


The two NUS Medicine researchers and co-founders of AGeM Bio, Dr Sarah Ho (left) and Dr Woo Jun Yung (right), with Clinical Associate Professor Yeo Tseng Tsai from the National University Hospital’s Division of Neurosurgery - The Straits Times

SINGAPORE: In the future, patients who suffer a relapse of the deadliest form of brain cancer may get a second shot at life with the help of a novel gene therapy developed by researchers from the National University of Singapore’s Yong Loo Lin School of Medicine (NUS Medicine).

The scientists behind the stem cell-based gene therapy are aiming to start a clinical trial for glioblastoma patients at the National University Hospital (NUH) by late 2025.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Aseanplus News

Indonesia president says ready to face all possibilities after US Supreme Court rejects Trump's global tariffs
Pezeshkian says Iran will not bow to pressure amid US nuclear talks
Asean News Headlines at 10pm on Saturday (Feb 21, 2026)
Health Ministry accelerates efforts to strengthen food safety control to achieve target by 2030
Japan issues travel alert for over 50 countries amid Middle East escalation and issues
'Still a shocker' - Audrey Fang's death: Family asks Spain court to extend suspect Mitchell Ong’s detention by two years
Indonesia did not pay US$1bil to join the Board of Peace, says Foreign Minister Sugiono
Thailand and Myanmar hold talks to re-engage with Naypidaw and Asean after strained ties
Golf-Rahm left out as DP World Tour grants LIV releases, Ryder Cup future uncertain
Turkish Red Crescent aid continues to flow into Gaza after the reopening of Rafah crossing

Others Also Read